Avanir Pharmaceuticals Inc  

(Public, NASDAQ:AVNR)   Watch this stock  
Find more results for AVNR
11.79
+0.11 (0.94%)
Oct 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.49 - 12.36
52 week 2.62 - 13.09
Open 11.67
Vol / Avg. 0.00/9.52M
Mkt cap 2.25B
P/E     -
Div/yield     -
EPS -0.47
Shares 192.76M
Beta 0.87
Inst. own 65%
Dec 8, 2014
Q4 2014 Avanir Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Oct 15, 2014
Avanir Pharmaceuticals Investor Briefing - Webcast
Sep 9, 2014
Avanir Pharmaceuticals Inc at Morgan Stanley Healthcare Conference - Webcast
Aug 13, 2014
Avanir Pharmaceuticals Inc at Canaccord Genuity Growth Conference
Aug 12, 2014
Avanir Pharmaceuticals Inc at Wedbush Securities Life Sciences Conference
Aug 5, 2014
Q3 2014 Avanir Pharmaceuticals Inc Earnings Call - Webcast
Aug 5, 2014
Q3 2014 Avanir Pharmaceuticals Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -44.35% -100.15%
Operating margin -41.54% -94.77%
EBITD margin - -93.68%
Return on average assets -50.42% -93.13%
Return on average equity -107.95% -272.93%
Employees 267 -
CDP Score - -

Address

Suite 200, 20 Enterprise
ALISO VIEJO, CA 92656
United States - Map
+1-949-3896700 (Phone)
+1-949-3896701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).

Officers and directors

Craig A. Wheeler Independent Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Keith A. Katkin President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Christine G. Ocampo CPA Principal Financial Officer, Vice President - Finance
Age: 41
Bio & Compensation  - Reuters
Joao Siffert M.D. Senior Vice President - Research and Development, Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Gregory J. Flesher Senior Vice President - Corporate Development, Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Rohan Palekar Senior Vice President, Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Mark H. N. Corrigan M.D. Director
Age: 56
Bio & Compensation  - Reuters
Hans Edgar Bishop Independent Director
Age: 49
Bio & Compensation  - Reuters
David J. Mazzo Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Corinne H. Nevinny Independent Director
Age: 54
Bio & Compensation  - Reuters